Other Events ·
Genmab board approves DKK 2,487 RSUs for directors at extraordinary general meeting
GMABGenmab A/S
At an Extraordinary General Meeting held on October 7, 2026, Genmab A/S shareholders approved the Board of Directors' proposal regarding remuneration for 2026. The resolution included the grant of a total of 5,300 restricted stock units (RSUs) to board members in accordance with the company's Remuneration Policy. Each RSU is awarded cost-free and provides a conditional right to receive one share of Genmab A/S, valued at DKK 2,487.00 based on the closing market price on the grant date. The units are scheduled to vest three years from the grant date. Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines.